Catalent Pharma Solutions and Nascent Biologics have signed a product development agreement in which Catalent will engineer a cell line expressing Nascent’s proprietary pritumumab antibody using Catalent’s GPEx technology, and will subsequently produce purified monoclonal antibody to support Nascent’s Phase I/II human clinical trials with pritumumab for treatment of brain cancers, such as astrocytomas and glioblastomas. GPEx technology is used to generate mammalian cells with high yields and st...